Undergraduate students from the University of Nottingham have been spending eight weeks in the FRAME Alternative Laboratory (FAL) to carry out a variety of projects and gain important laboratory experience. Dr Andy Bennett, Director of the FRAME Alternatives laboratory said Exposure of students to the use of non-animal methods early in their career is an [...]
A team of scientists from the UK and USA have announced a potential new treatment for cancer, based on the body’s own immune reaction to tumour cells. FRAME has welcomed the news because the research is based on human cell responses in actual patients, rather than using animal models. FRAME believes this kind of human-based [...]
The FRAME Alternatives Lab is able to differentiate human mononuclear blood cells into human osteoclasts (bone eating cells). Osteoclast dysfunction has been observed in a variety of bone diseases including osteoarthritis. The lab is currently investigating potential therapeutic agents which will decrease osteoclast activity in arthritis and reduce bone and joint damage.
The FRAME Alternatives Laboratory (FAL) was opened in 1991 as part of the University of Nottingham's medical school housed in the Queen's Medical Centre. Under the direction of Dr Richard Clothier, the FAL established itself as a leading laboratory for alternatives research. This tradition has continued under Dr Andrew Bennett who replaced Dr Clothier in [...]
As well as working with human cells, where possible the FRAME Alternatives Laboratory works with human patients and volunteers to increase understanding of human disease. Quite obviously, data obtained from human subjects is infinitely more relevant than data from animal models. Dietary studies in overweight and obese humans In conjunction with Clinicians and Physiologists at Nottingham University, [...]
Technological advancements that provide the opportunity to develop better and more reliable models are essential to translational research. At the FRAME Alternatives Laboratory at the University of Nottingham, PhD candidate Richard Maclennan has been working with the Zyoxel LiverChip device to determine its applicability and limitations for chronic toxicity testing. The LiverChip recreates the in [...]